Related Experiment Video

Updated: Jun 4, 2026

Identification of Orexin and Endocannabinoid Receptors in Adult Zebrafish Using Immunoperoxidase and Immunofluorescence Methods
08:37

Identification of Orexin and Endocannabinoid Receptors in Adult Zebrafish Using Immunoperoxidase and Immunofluorescence Methods

Published on: June 25, 2019

Agonist ligand discrimination by the two orexin receptors depends on the expression system

Jaana Putula1, Pauli M Turunen, Maria H Jäntti

  • 1Biochemistry and Cell Biology, Department of Veterinary Biosciences, University of Helsinki, P.O.B. 66, FIN-00014 University of Helsinki, Finland.

Neuroscience Letters
|March 3, 2011
PubMed

Insights

Orexin receptor agonists, often used to study OX(1) and OX(2) receptors, show unreliable selectivity and signal trafficking. This limits their usefulness in determining receptor expression and understanding cellular responses.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Receptor Biology

Background:

  • Orexin receptor antagonists are not widely available, leading to the common use of agonists for studying OX(1) and OX(2) receptors.
  • Agonist ligands are frequently employed to attribute cellular and tissue responses to specific orexin receptor subtypes.

Purpose of the Study:

  • To compare the subtype selectivity of native orexin-B and a synthetic variant, Ala(11), d-Leu(15)-orexin-B.
  • To evaluate the reliability of these agonists for determining orexin receptor subtype expression and function.

Main Methods:

  • Utilized recombinant HEK-293 and CHO-K1 cell lines expressing orexin receptors.
  • Measured calcium (Ca2+) elevation as a readout for receptor activation.
  • Compared the potency and selectivity of orexin-A, orexin-B, and Ala(11), d-Leu(15)-orexin-B across different cell lines.

Main Results:

  • Orexin-B exhibited 9-fold OX(2) selectivity in HEK-293 cells, while Ala(11), d-Leu(15)-orexin-B showed 23-fold selectivity.
  • Selectivity decreased in stable CHO-K1 cells (2.6-fold for orexin-B, 14-fold for Ala(11), d-Leu(15)-orexin-B).
  • Ligand selectivity was variable between cell lines, and agonist potencies varied significantly across different published responses.

Conclusions:

  • The tested orexin receptor agonists demonstrate insufficient and variable subtype selectivity.
  • Signal trafficking by orexin receptor ligands complicates agonist-based pharmacology.
  • The findings suggest that agonist-based approaches may be unreliable for precise orexin receptor subtype studies.

More Related Videos

High-throughput Analysis of Mammalian Olfactory Receptors: Measurement of Receptor Activation via Luciferase Activity12:02

High-throughput Analysis of Mammalian Olfactory Receptors: Measurement of Receptor Activation via Luciferase Activity

Published on: June 2, 2014

Live-cell Measurement of Odorant Receptor Activation Using a Real-time cAMP Assay09:11

Live-cell Measurement of Odorant Receptor Activation Using a Real-time cAMP Assay

Published on: October 2, 2017

Related Concept Videos

The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...